[Multiple sclerosis--current status of therapy].
The rational drug-treatment of multiple sclerosis on an immunological basis requires an acquaintance with the different forms of the disease course along with an understanding of the underlying pathomechanisms as well as a thorough knowledge of the chances and limitations of such a therapy. Besides some well established treatment regimens other approaches are presented which are currently evaluated in clinical trials and their effects and side effects are discussed.
Reichel
D
D
Neurologische Klinik und Poliklinik am Klinikum Erfurt.
Kölmel
H W
HW
D015761:4-Aminopyridine / Q000009:adverse effects / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination / Q000187:drug effects; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D003520:Cyclophosphamide; D015761:4-Aminopyridine; D001379:Azathioprine